NADiA ProsVue – accurate predictor of prostate cancer recurrence in radical prostatectomy patients

The authors aimed to determine whether their product could be used to determine prostate cancer-specific mortality and other outcomes after radical prostatectomy.

NADiA ProsVue is a device that determines the likelihood that a prostate cancer patient will experience recurrent cancer after receiving a radical prostatectomy (surgery to remove the prostate), by testing prostate specific antigen (PSA – protein in the blood that is elevated when cancer is present) levels in the blood. This product has been launched in the USA. However, it has not previously been used to  which the followipredict prostate cancer-specific mortality (death specifically from prostate cancer).

The authors aimed to determine whether NADiA ProsVue could be used to predict prostate cancer-specific mortality in patients who received a radial prostatectomy.

This study involved 304 patients and a follow-up period of 8-11 years. PSA was the independent predictor in determining risk of recurrence and prostate cancer-specific survival where a PSA of less than 2.0pg/ml indicated a low risk of the cancer recurring.

The average overall survival (time from patient diagnosis until death by any cause) in patients with less than 2.0 pg/ml was 11 years in comparison to those with more than 2.0pg/ml, who had an overall survival of 9.2 years. PSA level less than 2.0pg/ml was the most important risk factor for both recurrence,  where patients were over 18 times more likely to experience cancer recurrence,  and prostate cancer-specific mortality, where patients were over 20 times more likely to experience prostate cancer-specific mortality. Advanced analysis determined that patients with less than 2.0pg/ml had a 94% reduced risk of experiencing prostate cancer-specific mortality when compared to patients with more than 2.0 pg/ml.

NADiA ProsVue can be used to determine prostate cancer-specific survival in patients who receive a radical prostatectomy.

Please consult your doctor if you are considering a radical prostatectomy and have questions about the benefit of the use of NADiA ProsVue post-treatment.